BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival

BioSpace

Indirect comparisons between BridgeBio's Attruby and Pfizer's tafamidis products showed a numerical survival benefit with the biotech's drug.

pharminent May 12, 2026 (Last updated: May 12, 2026)

BioSpace

Indirect comparisons between BridgeBio’s Attruby and Pfizer’s tafamidis products showed a numerical survival benefit with the biotech’s drug.

Related Stories